Staging Cardiac Damage in Patients With Symptomatic Aortic Valve Stenosis.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
30 07 2019
Historique:
received: 28 02 2019
revised: 26 04 2019
accepted: 06 05 2019
entrez: 27 7 2019
pubmed: 28 7 2019
medline: 22 5 2020
Statut: ppublish

Résumé

In severe aortic stenosis (AS), patients often show extra-aortic valvular injury. Recently, a new staging system for severe AS has been proposed on the basis of the extent of cardiac damage. The present study evaluated the prevalence and prognostic impact of these different stages of cardiac damage in a large, real-world, multicenter cohort of symptomatic severe AS patients. From the ongoing registries from 2 academic institutions, a total of 1,189 symptomatic severe AS patients were selected and retrospectively analyzed. According to the extent of cardiac damage on echocardiography, patients were classified as Stage 0 (no cardiac damage), Stage 1 (left ventricular damage), Stage 2 (mitral valve or left atrial damage), Stage 3 (tricuspid valve or pulmonary artery vasculature damage), or Stage 4 (right ventricular damage). Patients were followed for all-cause mortality and combined endpoint (all-cause mortality, stroke, and cardiac-related hospitalization). On the basis of the proposed classification, 8% of patients were classified as Stage 0, 24% as Stage 1, 49% as Stage 2, 7% as Stage 3, and 12% as Stage 4. On multivariable analysis, cardiac damage was independently associated with all-cause mortality and combined outcome, although this was mainly determined by Stages 3 and 4. In this large multicenter cohort of symptomatic severe AS patients, stage of cardiac injury as classified by a novel staging system was independently associated with all-cause mortality and combined endpoint, although this seemed to be predominantly driven by tricuspid valve or pulmonary artery vasculature damage (Stage 3) and right ventricular dysfunction (Stage 4).

Sections du résumé

BACKGROUND
In severe aortic stenosis (AS), patients often show extra-aortic valvular injury. Recently, a new staging system for severe AS has been proposed on the basis of the extent of cardiac damage.
OBJECTIVES
The present study evaluated the prevalence and prognostic impact of these different stages of cardiac damage in a large, real-world, multicenter cohort of symptomatic severe AS patients.
METHODS
From the ongoing registries from 2 academic institutions, a total of 1,189 symptomatic severe AS patients were selected and retrospectively analyzed. According to the extent of cardiac damage on echocardiography, patients were classified as Stage 0 (no cardiac damage), Stage 1 (left ventricular damage), Stage 2 (mitral valve or left atrial damage), Stage 3 (tricuspid valve or pulmonary artery vasculature damage), or Stage 4 (right ventricular damage). Patients were followed for all-cause mortality and combined endpoint (all-cause mortality, stroke, and cardiac-related hospitalization).
RESULTS
On the basis of the proposed classification, 8% of patients were classified as Stage 0, 24% as Stage 1, 49% as Stage 2, 7% as Stage 3, and 12% as Stage 4. On multivariable analysis, cardiac damage was independently associated with all-cause mortality and combined outcome, although this was mainly determined by Stages 3 and 4.
CONCLUSIONS
In this large multicenter cohort of symptomatic severe AS patients, stage of cardiac injury as classified by a novel staging system was independently associated with all-cause mortality and combined endpoint, although this seemed to be predominantly driven by tricuspid valve or pulmonary artery vasculature damage (Stage 3) and right ventricular dysfunction (Stage 4).

Identifiants

pubmed: 31345429
pii: S0735-1097(19)35383-5
doi: 10.1016/j.jacc.2019.05.048
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

538-549

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

E Mara Vollema (EM)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Mohammed R Amanullah (MR)

Department of Cardiology, National Heart Centre Singapore, Singapore.

Arnold C T Ng (ACT)

Department of Cardiology, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.

Pieter van der Bijl (P)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Francesca Prevedello (F)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Yoong Kong Sin (YK)

Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore.

Edgard A Prihadi (EA)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Nina Ajmone Marsan (NA)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Zee Pin Ding (ZP)

Department of Cardiology, National Heart Centre Singapore, Singapore.

Philippe Généreux (P)

Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey; Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montréal, Quebec, Canada.

Philippe Pibarot (P)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Martin B Leon (MB)

Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; New York-Presbyterian Hospital/Columbia University, Medical Center, New York, New York.

Jagat Narula (J)

Mount Sinai Hospital, New York, New York.

See Hooi Ewe (SH)

Department of Cardiology, National Heart Centre Singapore, Singapore.

Victoria Delgado (V)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Jeroen J Bax (JJ)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: j.j.bax@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH